Takayasu's arteritis is a rare autoimmune disease that affects the large blood vessels in the body, particularly the aorta (the main artery exiting the heart) and its main branches. It primarily affects women of childbearing age but can occur in both men and women of any age.
The exact cause of Takayasu's arteritis is unknown, but it is believed to be an autoimmune disorder in which the body's immune system attacks the lining of the blood vessels. Genetics may play a role in its development, as certain genetic variations have been linked to an increased risk of developing the disease.
The symptoms of Takayasu's arteritis can vary widely depending on which blood vessels are affected but often include fatigue, muscle and joint pain, fever, and a general feeling of illness. As the disease progresses, it can cause damage to the affected blood vessels, leading to reduced blood flow and potentially severe complications, such as aneurysms, strokes, or heart failure.
Takayasu’s arteritis is a chronic disease - people can live with it for many years, sometimes without being aware. It requires lifelong treatment. However, the progression and prognosis of Takayasu’s arteritis depend on the individual’s disease severity and response to treatment.
Treatment typically involves medications to suppress the immune system, reduce inflammation, and manage any complications. The treatment's primary aim is to reduce the risk of complications and prevent events such as heart attack, stroke, and organ damage.
Takayasu’s arteritis is mostly diagnosed before the age of 40. Awareness of your genetic susceptibility to developing this disease may greatly aid in the diagnosis thereof. Early recognition and prompt treatment can help manage symptoms and prevent complications.
Interested in trying the BioCertica DNA Autoimmune kit? Click here and add Autoimmune Diseases to your cart for only R1699.
If you own any other BioCertica DNA kit, you can instantly unlock your Autoimmune Disease results for only R659* in-app.
*Terms and conditions apply: Pharmacogenetics results are R1999 in-app.